Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00427973 · ClinicalTrials.gov registry record · Phase 2
AZD2171 in Treating Patients With Locally Advanced Unresectable or Metastatic Liver Cancer
A Phase 2 study, sponsored by National Cancer Institute (NCI).
- Terminated
- Registry status
- Phase 2
- Development phase
- 17
- Enrollment target
NCT00427973: Clinical Trial Phase 2 study, sponsored by National Cancer Institute (NCI).
NCT00427973 is a Phase 2 study that was terminated before completion, run by National Cancer Institute (NCI). The registered enrollment target is 17 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00427973, a Phase 2 study, was terminated before completion, sponsored by National Cancer Institute (NCI).
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 17 participants
- Enrollment target
Study Summary
This phase II trial is studying how well AZD2171 works in treating patients with locally advanced unresectable or metastatic liver cancer. AZD2171 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor
Interventions
- OTHER laboratory biomarker analysis
- OTHER pharmacological study
- PROCEDURE computed tomography
- PROCEDURE dynamic contrast-enhanced magnetic resonance imaging
- DRUG cediranib maleate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2009-05 |
| Est. Completion | 2012-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00427973
The ClinicalTrials.gov registry entry for NCT00427973 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which laboratory biomarker analysis is the first listed.
NCT00427973 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00427973 about?
NCT00427973 is a clinical study titled "AZD2171 in Treating Patients With Locally Advanced Unresectable or Metastatic Liver Cancer". This phase II trial is studying how well AZD2171 works in treating patients with locally advanced unresectable or metastatic liver cancer. AZD2171 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor
What is the current status of trial NCT00427973?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 17 participants. The study started on 2009-05. Estimated completion is 2012-03.
What interventions are being tested in trial NCT00427973?
The interventions under investigation include: laboratory biomarker analysis (OTHER), pharmacological study (OTHER), computed tomography (PROCEDURE), dynamic contrast-enhanced magnetic resonance imaging (PROCEDURE), cediranib maleate (DRUG).
Who is sponsoring clinical trial NCT00427973?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.